Chemotherapy-Induced Lung Disease

Clinical Pulmonary Medicine

Volumn 11, Issue 2, 2004, Pages 84-91

  Vander Els, Nicholas J ^a   Stover, Diane E ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NONE   (United States)

Author keywords

Cancer; Chemotherapy; Pulmonary toxicity

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIMETABOLITE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; NITROSOUREA DERIVATIVE; NUCLEOSIDE DERIVATIVE; PACLITAXEL; PROCARBAZINE; RETINOIC ACID; SEMUSTINE; TAXANE DERIVATIVE; VINBLASTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; BRONCHIOLITIS; BRONCHOSPASM; CANCER CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CAPILLARY PERMEABILITY; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LUNG HEMORRHAGE; LUNG INJURY; LUNG METASTASIS; LUNG TOXICITY; LYMPH NODE DISSECTION; OXYGEN THERAPY; PLEURA EFFUSION; RECURRENT INFECTION; REVIEW; VEIN OCCLUSION;

EID: 1542510612     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cpm.0000117766.07651.f8     Document Type: Review

References (60)

1. Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease: part I. Am Rev Resp Dis. 1986;133:321-340.
2. Rossi SE, Erasmus JJ, McAdams, et al. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics. 2000;20:1245-1259.
3. Sleijffer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617-624.
4. Burger RM, Pesach J, Horowitz SB. Activated bleomycin: a transient complex of drug, iron and oxygen that degradates DNA. J Biol Chem. 1981;256:11636-11644.
5. Sleijffer S, Vujaskovic Z, Limburg PC, et al. Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicity. Cancer. 1998;82: 970-974.
6. Giri SN, Hyed DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax. 1993;48:959-966.
7. Nici L, Santos-Moore A, Kuhn C, et al. Modulation of bleomycin-induced pulmonary toxicity in the hamster by the antioxidant amifostine. Cancer. 1998;83:2008-2014.
8. Hoorn CM, Wagner JG, Petry TW, et al. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol. 1994;130:87-94.
9. Dirix LY, Libura M, Libura J, et al. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs. 1997;8:859-868.
10. Akoun GM, Mayawd CM, Toubod JL, et al. Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease. Thorax. 1987;42: 652-655.
11. White DA, Rankin JA, Stover DE, et al. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Resp Dis. 1989;139:18-21.
12. Fuhrman C, Parrot A, Wislez M, et al. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med. 2001;164:1186-1191.
13. Ravenel J, McAdams P, Plankel J, et al. Sarcoidosis induced by interferon therapy. Am J Roentgenol. 2001;177:199-201.
14. Vander Els NJ, Gerdes H. Sarcoidosis and IFN-alpha therapy. Chest. 2000;117:294.
15. Anderson BS, Luna MA, Yee C, et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990;65:1079-1084.
16. Frankel SR, Eardley A, Lauwers G, et al. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med. 1992;117:292-296.
17. Castro M, Veeder MH, Mailliard JA, et al. A prospective study of pulmonary function in patients receiving mitomycin. Chest. 1996;109: 939-944.
18. Rivera MP, Kris MG, Gralla RV, et al. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. Am J Clin Oncol. 1995;18:245-250.
19. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286-291.
20. Jules-Elyse K, White D. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990;11:1-20.
21. Colis CH. Lung damage of cytoxic drugs. Pharmacology. 1980;4:17-21.
22. Simpson AB, Paul J, Graham J, et al. Fatal bleomycin pulmonary toxicity in the West of Scotland 1991-95: a review of germ-cell tumors. Br Cancer. 1998;78:1061-1066.
23. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restrictive necessary? J Urol. 1998;160:1347-1352.
24. Wolkowicz J, Sturgeon J, Rawji M, et al. Bleomycin-induced pulmonary function abnormalities. Chest. 1992;101:97-101.
25. Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early stage Hodgkin's disease. J Clin Oncol. 1998;14:1297-1305.
26. VanderEls NJ, Sorhage F, Bach AM, et al. Abnormal flow volume loops in patients with intrathoracic Hodgkin's disease. Chest. 2000;117:1256-1261.
27. Todd NW, Peters WP, Ost AH, et al. pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis. 1993;147:1264-1270.
28. Wu M, Kelley MR, Hanson WK, et al. Reduction of BCNU toxicity to lung cells by high-level expression of O6-methyl-guanine-DNA methyltransferase. Am J Physical Lung Cell Mol Physiol. 2001;280:L755-L761.
29. Nathan CF, Arrick BA, Murray HW, et al. Tumor cell antioxidant defenses: inhibition of the glutathione redox cycle enhances macrophage mediated cytolysis. J Exp Med. 1981;153:766-782.
30. Abushama Am, Sporn TA, Felz RJ. Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. Am J Physiol Lung Cell Med. 2002;283:L336-L345.
31. Durant JR, Norgard MJ, Murod TH, et al. Pulmonary toxicity associated with bichloroethylnitrosourea (BCNU) Ann Intern Med. 1979;90:191-194.
32. Allesandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant. 2000;25:309-313.
33. Rubio C, Hill NE, Milan S, et al. Idiopathic pneumonia syndrome after high dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer. 1997;75:1044-1048.
34. O'Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy With carmustine (BCNU) in childhood. N Engl J Med. 1990;323:378-382.
35. Orwoll ES, Kiessling P, Patterson R. Interstitial pneumonia from mitomycin. Ann Intern Med. 1978;89:352-355.
36. Rowensky EK, Donehower RC. Drug therapy: paclitaxel (Taxol) N Engl J Med. 1995;332:1004-1014.
37. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002;94:847-853.
38. Ramanathan RK, Reddy VU, Holbert JM, et al. Pulmonary infiltrates following administration of paclitaxel. Chest. 1996;110:289-292.
39. Fujimori K, Yokoyama A, Kunta Y, et al. Paclitaxel-induced cell-medicated hypersensitivity pneumonitis. Oncology. 1998;55:340-344.
40. Dimopoulou I, Galan H, Dafni V, et al. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer. 2002;94:452-458.
41. Morris MV, Santamauro J, Shia J, et al. Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estra-mustine. Urology. 2002;60:1111vi-1111xi.
42. Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999;10:943-947.
43. White DA, Orenstein M, Godwin TA, et al. Chemotherapy-associated pulmonary toxic reactions during treatment for breast cancer. Arch Intern Med. 1984;144:953-956.
44. Bernstein M, Sobel DB, Winner RS. Noncardiogenic pulmonary edema following injections of methotrexate into the cerebrospinal fluid. Cancer. 1982;50:866-868.
45. Walden PAM, Mitchell-Heffs PF, Coppin C, et al. Pleurisy and methotrexate treatment. BMJ. 1977;2:867.
46. Carson CW, Cannon GW, Egger M, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987;16:186-195.
47. Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Ann Intern Med. 1997;127:356-364.
48. Sustman HD, Matthay RA, Putman CE. Methotrexate-induced pneumonitis. Medicine. 1976;55:371-388.
49. Azzoli CG, Miller VA, Krug LM, et al. Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am J Clin Oncol. 2003;26:247-251.
50. Roychowdhury DF, Cassidy CA, Peterson P, et al. A report on serious pulmonary toxicity associated with gemcitabine-base therapy. Invest New Drugs. 2002;20:311-315.
51. Nelson R, Tarrassoff P. Dyspnea with gemcitabine is commonly seen, often disease related, transient, and rarely severe. Eur J Cancer. 1995; 31(suppl 5):197-198.
52. Gupta N, Ahmed I Steinberg H, et al. Gemcitabine-induced pulmonary toxicity case report and review of the literature. Am J Clin Oncol. 2002;25:96-100.
53. Joerger M, Gunz A, Speich R, et al. Gemcitabine-related pulmonary toxicity. Swiss Med Weekly. 2002;132:17-20.
54. Boiselle PM, Marvin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Asst Tomogr. 2000;24:977-988.
55. Vander Els NJ, Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest. 1998;114: 1779-1781.
56. Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol. 1993;4:371-375.
57. Helman DL, Byrd JC, Ales NC, et al. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphproliferative syndromes. Chest. 2002;122:785-790.
58. Stoica GS, Greenberg HE, Rossoff LJ. Corticosteroid responsive fludarabine, pulmonary toxicity. Am J Clin Oncol. 2002;25:340-341.
59. Garg S, Garg MS, Basmoji N. Multiple pulmonary nodules: an unusual presentation of fludarabine toxicity: case report and review of the literature. Am J Hematol. 2002;70:241-245.
60. Hochster HS, Oken MM, Winter JN, et al. Phase 1 study of fludarabine plus cyclophosphamide in patients with previously treated low-grade lymphoma: results and long-term follow-up: a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000;18:987-994.